These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11199947)

  • 1. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.
    Romano S; Goodman W; Tamura R; Gonzales J
    J Clin Psychopharmacol; 2001 Feb; 21(1):46-52. PubMed ID: 11199947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.
    Romano SJ; Halmi KA; Sarkar NP; Koke SC; Lee JS
    Am J Psychiatry; 2002 Jan; 159(1):96-102. PubMed ID: 11772696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
    Sayyah M; Boostani H; Pakseresht S; Malayeri A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):362-5. PubMed ID: 20035818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.
    Amsterdam JD; Garcia-España F; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Schweizer E; Beasley C
    J Clin Psychopharmacol; 1998 Dec; 18(6):435-40. PubMed ID: 9864074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.
    Martenyi F; Brown EB; Zhang H; Koke SC; Prakash A
    Br J Psychiatry; 2002 Oct; 181():315-20. PubMed ID: 12356658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.
    Montgomery SA; McIntyre A; Osterheider M; Sarteschi P; Zitterl W; Zohar J; Birkett M; Wood AJ
    Eur Neuropsychopharmacol; 1993 Jun; 3(2):143-52. PubMed ID: 8364350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
    Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
    J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
    Liebowitz MR; Turner SM; Piacentini J; Beidel DC; Clarvit SR; Davies SO; Graae F; Jaffer M; Lin SH; Sallee FR; Schmidt AB; Simpson HB
    J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1431-8. PubMed ID: 12447029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine in the prevention of depressive recurrences: a double-blind study.
    Gilaberte I; Montejo AL; de la Gandara J; Perez-Sola V; Bernardo M; Massana J; Martin-Santos R; Santiso A; Noguera R; Casais L; Perez-Camo V; Arias M; Judge R;
    J Clin Psychopharmacol; 2001 Aug; 21(4):417-24. PubMed ID: 11476126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.
    Amsterdam JD; Shults J
    Am J Psychiatry; 2010 Jul; 167(7):792-800. PubMed ID: 20360317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.
    Koran LM; Hackett E; Rubin A; Wolkow R; Robinson D
    Am J Psychiatry; 2002 Jan; 159(1):88-95. PubMed ID: 11772695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
    Reimherr FW; Amsterdam JD; Quitkin FM; Rosenbaum JF; Fava M; Zajecka J; Beasley CM; Michelson D; Roback P; Sundell K
    Am J Psychiatry; 1998 Sep; 155(9):1247-53. PubMed ID: 9734550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
    Fineberg NA; Pampaloni I; Pallanti S; Ipser J; Stein DJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):313-22. PubMed ID: 17917549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1998 Jun; 18(3):185-92. PubMed ID: 9617976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.